Company intelligence / Profile preview

mementor

Leipzig, Sachsen/Saxony, Germanymementor.net ↗

Ownership: Private
Development stage: Other

Overview

The flagship product "somnio" has demonstrated clinical efficacy in reducing insomnia symptoms by 50% after several months of use. Users also experienced reduced depression symptoms, decreased nightly wake time by an average of 31 minutes, and fell asleep about 18 minutes faster. These effects were sustained for at least a year post-treatment initiation.

Therapeutic areas: Psychiatry
Modalities: Non-pharmacological therapyDevice (digital therapeutic app)
Industry: Digital Health Medical Devices

Partnerships

ResMed integration and distribution partnership within Germany

Beyond the preview

Go deeper on mementor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mementor.

Explore the full profile